| |
| |
|
| Insider
Information: |
Johnson John H |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
1,384,984 |
|
|
Indirect Shares
|
4,000 |
|
|
| Direct
Value |
$46,937 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,388,984 |
|
|
| Total
Value |
$46,937 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Savient Pharmaceuticals Inc |
SVNTQ |
CEO & President, Direc... |
2011-11-21 |
270,000 |
2011-11-18 |
4,000 |
Premium* |
|
|
Dendreon Corp |
DNDN |
Pres & Chief Executive... |
2014-07-03 |
1,071,125 |
2011-08-18 |
0 |
Premium* |
|
|
Melinta Therapeutics, Inc |
MLNT |
Chief Executive Office... |
2019-06-27 |
37,400 |
2014-05-23 |
0 |
Premium* |
|
|
Sucampo Pharmaceuticals, Inc. |
SCMP |
Director |
2018-02-13 |
0 |
2016-06-02 |
0 |
Premium* |
|
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2020-07-02 |
0 |
2016-06-17 |
0 |
Premium* |
|
|
Strongbridge Biopharma Plc |
SBBP |
Chief Executive Office... |
2021-10-05 |
0 |
2019-05-15 |
0 |
Premium* |
|
|
Axogen Inc |
AXGN |
Director |
2023-06-01 |
6,459 |
2023-06-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AXGN |
Axogen Inc |
Director |
– • – |
2023-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,459 |
6,459 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Chief Executive Officer |
• • – |
2021-10-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(610,092) |
0 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Chief Executive Officer |
• • – |
2021-10-01 |
4 |
D |
$2.06 |
$689,828 |
D/D |
(334,868) |
610,092 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Chief Executive Officer |
• • – |
2021-07-02 |
4 |
D |
$3.08 |
$156,670 |
D/D |
(50,867) |
944,960 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Chief Executive Officer |
• • – |
2021-04-08 |
4 |
D |
$2.68 |
$46,431 |
D/D |
(17,325) |
995,827 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Chief Executive Officer |
• • – |
2021-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
491,000 |
1,013,152 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Chief Executive Officer |
• • – |
2020-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
315,000 |
522,152 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Director |
– • – |
2020-07-02 |
4 |
D |
$18.00 |
$131,058 |
D/D |
(7,281) |
0 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Director |
– • – |
2020-07-02 |
4 |
D |
$18.00 |
$237,492 |
D/D |
(13,194) |
0 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Director |
– • – |
2020-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
7,281 |
20,475 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Executive Chairman |
• • – |
2020-05-15 |
4 |
D |
$2.86 |
$43,895 |
D/D |
(15,348) |
207,152 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Executive Chairman |
• • – |
2020-04-08 |
4 |
A |
$0.00 |
$0 |
D/D |
182,500 |
222,500 |
0 |
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Chief Executive Officer |
• • – |
2019-06-27 |
4 |
S |
$5.57 |
$72,441 |
D/D |
(13,000) |
37,400 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
4,194 |
13,194 |
0 |
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2019-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
50,400 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Director |
– • – |
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
40,000 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Director |
– • – |
2018-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
9,000 |
0 |
- |
|
| SCMP |
Sucampo Pharmaceuticals, ... |
Director |
– • – |
2018-02-13 |
4 |
D |
$18.00 |
$92,340 |
D/D |
(5,130) |
0 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Director |
– • – |
2017-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
3,000 |
0 |
- |
|
| SCMP |
Sucampo Pharmaceuticals, ... |
Director |
– • – |
2017-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,130 |
14,930 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Director |
– • – |
2016-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
3,000 |
0 |
- |
|
| SCMP |
Sucampo Pharmaceuticals, ... |
Director |
– • – |
2016-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,800 |
9,800 |
0 |
- |
|
| DNDN |
Dendreon Corp |
Pres & Chief Executive Officer |
• • – |
2014-07-03 |
4 |
D |
$2.29 |
$27,686 |
D/D |
(12,090) |
1,071,125 |
0 |
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2014-05-23 |
4 |
B |
$9.10 |
$90,980 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| DNDN |
Dendreon Corp |
Pres & Chief Executive Officer |
• • – |
2014-04-03 |
4 |
D |
$2.93 |
$27,715 |
D/D |
(9,459) |
1,083,215 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
